Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Safety, tolerability and pharmacokinetic study of BIIX 1 XX in healthy male volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BIIX 1 XX, rising doses | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BIIX 1 XX inhalation solution | Drug | single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with adverse events | up to 22 days | |
| Number of patients with clinically relevant changes in vital parameters (Blood pressure, Pulse rate) | up to 8 days after drug administration | |
| Number of patients with clinically relevant changes in electrocardiogram (ECG) | up to 8 days after drug administration | |
| Number of patients with clinically relevant changes in impedance cardiography | pre-dose, 10 and 30 minutes after administration | |
| Number of patients with clinically relevant changes in cutaneous microcirculation | pre-dose, 10 and 30 minutes after administration | |
| Number of patients with clinically relevant changes in safety laboratory parameters | up to 8 days after drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum concentration of the drug in plasma (Cmax) | up to 168 hours after drug administration | |
| Area under the plasma drug concentration-time curve from zero time to the last time point of measurement (AUC0-tz) | up to 168 hours after drug administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug |
|
| Terminal half-life of the analyte in plasma (t1/2) | up to 168 hours after drug administration |
| Clearance, divided by f (CL/f) | up to 168 hours after drug administration |